Navigation Links
Monogram Announces Third Quarter 2007 Financial Results
Date:10/24/2007

uthorize reimbursement for our products and services and the amount of such reimbursement that may be allowed; whether the FDA or any other agency will decide to further regulate our products or services, including Trofile; whether the draft guidance on Multivariate Index Assays issued by FDA will be subsequently determined to apply to our current or planned products; whether we will encounter problems or delays in automating our processes; the ultimate validity and enforceability of our patent applications and patents; the possible infringement of the intellectual property of others; whether licenses to third party technology will be available; whether we are able to build brand loyalty and expand revenues; restrictions on the conduct of our business imposed by the Pfizer, Merrill Lynch and other debt agreements; the impact of additional dilution if our convertible debt is converted to equity; and whether we will be able to raise sufficient capital in the future, if required. For a discussion of other factors that may cause actual events to differ from those projected, please refer to our most recent annual report on Form 10-K and quarterly reports on Form 10-Q, as well as other subsequent filings with the Securities and Exchange Commission. We do not undertake, and specifically disclaim any obligation, to revise any forward-looking statements to reflect the occurrence of anticipated or unanticipated events or circumstances after the date of such statements.

PhenoSense, PhenoSenseGT, Trofile, HERmark and VeraTag are trademarks of Monogram Biosciences, Inc. Heceptin is a registered trademark of Genentech, Inc. Selzentry is a trademark and Celsentri is a registered trademark of Pfizer Inc. - financials to follow - MONOGRAM BIOSCIENCES, INC. SELECTED STATEMENT OF OPERATIONS DATA (In thousands, except per share amounts) (Unaudited)

Three Months Ended Nine Months Ended

Septemb
'/>"/>

SOURCE Monogram Biosciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related biology technology :

1. Speaker announces business members of IT Task Force
2. Doyle announces technology tax credits for Berbee
3. Doyle announces new energy, global warming policies
4. Doyle announces $80M renewable energy strategy
5. GE announces first installation of Discovery VCT
6. UWM announces winners of RGI awards
7. Third Wave announces two senior management appointments
8. Mirus announces new method for making antibodies
9. Merge announces sofware updates, upcoming acquisition
10. Small Tree announces ethernet solution for Apple Xserv G5
11. TEKLYNX International announces new RFID software
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... In 2013, Lawrence Livermore National ... Security LLC (LLNS), was awarded more than ... laser system for the European Union's Extreme Light ... the Czech Republic. , When commissioned to its ... " High repetition-rate Advanced Petawatt Laser System " ...
(Date:8/27/2014)... 27, 2014 Reportlinker.com announces that a ... catalogue: Global Chelating Agents Market 2014-2018 ... About Chelating Agent A chelating agent is a ... metal ions, thereby forming a metal-ion complex. It ... on chemical processes, formulations, and the environment by ...
(Date:8/27/2014)... NEW YORK , Aug. 27, 2014 ... of Guggenheim Partners, today announced the hiring of veteran ... and senior equity analyst. Mr. Butler will focus on ... brings our team a wealth of experience and a ... Dante Ferrarie , Senior Managing Director and Head of ...
(Date:8/27/2014)... , Aug. 27, 2014  ARCH Venture ... firms investing in the development of seed and ... eighth venture fund closed with more than $400 ... its $250 million subscription target by more than ... VIII shows the strength and potential of our ...
Breaking Biology Technology:LLNL Synchs up with ELI Beamlines on Timing System 2LLNL Synchs up with ELI Beamlines on Timing System 3Global Chelating Agents Market 2014-2018 2Global Chelating Agents Market 2014-2018 3Global Chelating Agents Market 2014-2018 4Guggenheim Securities Hires Analyst Charles "Tony" Butler to Expand Healthcare Coverage 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... 28, 2011 Arteriocyte®, a leading clinical stage ... Hopkinton, Massachusetts that develops proprietary stem cell and ... the Food and Drug Administration (FDA) to initiate ... MAR01™ technology in the treatment of Critical Limb ...
... in Spanish and French . , WALNUT ... this fibrous diet consisting mainly of the tough to degrade plant ... to most animals, ruminants manage to extract all they need to ... the cow, or rather the network of organisms working unseen in ...
... of gold nanoparticles and viral particles, woven together and ... a distinctive mix of hard, metallic nanoparticles and ... very stuff of life, DNA marks a remarkable ... materials to create infinitesimal devices. The research, done ...
Cached Biology Technology:Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 2Arteriocyte Receives FDA Approval to Move Forward with Critical Limb Ischemia Trial 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 2How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 3How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 4How now, inside the cow: Nearly 30,000 novel enzymes for biofuel production improvements 5A mix of tiny gold and viral particles -- and the DNA ties that bind them 2
(Date:8/28/2014)... 2014 Dyslexia, the most commonly diagnosed learning ... reading disability that occurs when the regions of ... normally. , The use of non-invasive functional neuroimaging ... disrupted in dyslexia. However, most prior work has ... regions, leaving a gap in our understanding of ...
(Date:8/28/2014)... Washington, Oregon, northern California, and Alaska totaled 515 million ... 2014, an increase of more than 10 percent compared ... Service,s Pacific Northwest Research Station reported today. During this ... percent to 247 million board feet. , The total ... 5 percent to $390 million in the same quarter, ...
(Date:8/27/2014)... FREMONT, Calif. , Aug. 27, 2014  WaferGen ... completed its previously announced underwritten public offering of units ... $10,000 per unit for gross proceeds of $20 million, ... expenses payable by the Company.  The shares and warrants ... Each unit sold in the offering consists ...
Breaking Biology News(10 mins):Dyslexic readers have disrupted network connections in the brain 2West coast log exports up, lumber exports down in second quarter of 2014 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 2WaferGen Bio-Systems Announces Successful Completion of Public Offering Raising $20 Million 3
... N.C. In a finding that confirms what many ... younger women who undergo hysterectomies face a nearly two-fold ... published in the December issue of the journal ... track over time the actual hormonal impact of woman ...
... November 14, 2011 The possibility that functional, ... cells, such as embryonic stem cells (ESCs) and induced ... challenges of stem cell research, but is also one ... regenerative medicine. Developmental biology has played a central role ...
... CLEVELAND -- An estimated 300,000 people in North ... a progressive loss of motor control. Patients with generalized ... uncontrolled twisting and turning in awkward, sometimes painful postures. ... the disorder can have a devastating impact on quality ...
Cached Biology News:Hysterectomy increases risk for earlier menopause among younger women 2Self-organized pituitary-like tissue from mouse ES cells 2Self-organized pituitary-like tissue from mouse ES cells 3Self-organized pituitary-like tissue from mouse ES cells 4University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 2University Hospitals Case Medical Center unlocks mystery of dystonia with advanced imaging 3
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
...
Assay Diluent 500 mls...
Biology Products: